Susan Melin to Female
This is a "connection" page, showing publications Susan Melin has written about Female.
Connection Strength
0.115
-
Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May; 2(5):445-9.
Score: 0.022
-
Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat. 2017 Jun; 163(2):199-205.
Score: 0.011
-
Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614.
Score: 0.011
-
Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M. Does age predict outcome in patients with inflammatory breast cancer? Am Surg. 2014 Aug; 80(8):E221-4.
Score: 0.009
-
Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. . 2013 Jun; 14(6):476-80.
Score: 0.008
-
Drafts BC, Twomley KM, D'Agostino R, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013 Aug; 6(8):877-85.
Score: 0.008
-
Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013 Apr; 205(4):397-401.
Score: 0.008
-
Chaosuwannakit N, D'Agostino R, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010 Jan 01; 28(1):166-72.
Score: 0.007
-
Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Mar; 61(3):453-8.
Score: 0.006
-
Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006 Apr; 243(4):472-8.
Score: 0.005
-
Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006; 37(1):7-14.
Score: 0.005
-
Blackstock AW, Farmer MR, Lovato J, Mishra G, Melin SA, Oaks T, Aklilu M, Clark PB, Levine EA. A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):455-60.
Score: 0.005
-
Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol. 2005 Aug; 28(4):345-50.
Score: 0.005
-
Tomlinson SK, Melin SA, Higgs V, White DR, Savage P, Case D, Blackstock AW. Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. BMC Cancer. 2002 May 02; 2:9.
Score: 0.004